MedPath

Evaluation of the effect of saffron extract and vitamin A supplement in the control and treatment of dry eye symptoms

Phase 2
Recruiting
Conditions
Dry eye syndrome.
Dry eye syndrome of unspecified lacrimal gland
H04. 129
Registration Number
IRCT20210926052587N1
Lead Sponsor
Semnan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
120
Inclusion Criteria

Inclusion criteria are patients with dry eye. Thus, if a person has a Schmermer test (or SMTUBE) (with anesthesia) less than 10 mm and a tear film rupture test (TBUT) less than 10 seconds, it is a diagnosis of dry eye and will be included in the study.

Exclusion Criteria

Previous history of eye surgery
Previous history of eye disorders
Systemic disorders
Using a contact lense (including soft or hard type)
Failure to fill out the informed consent form

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Dry eye (in the present study, dry eye based on the results of the Surface Eye Disease Index (OSDI=13) and TBUT non-invasive (less than 10 seconds), Shermer 1 test (with anesthesia) less than 10 mm and color Eye surface plasticity (OSS) will be defined (color>> 5 corneal points and> 9 conjunctival or eyelid edge points). Timepoint: Measurement of dry eye at the beginning of the study (before the intervention) and 90 days after the start of medication. Method of measurement: (in the present study, dry eye based on the results of the Surface Eye Disease Index (OSDI=13) and TBUT non-invasive (less than 10 seconds), Shermer 1 test (with anesthesia) less than 10 mm and color Eye surface plasticity (OSS) will be defined (color>> 5 corneal points and> 9 conjunctival or eyelid edge points).
Secondary Outcome Measures
NameTimeMethod
Best corrected visual acuity. Timepoint: Day 0 and Day 90. Method of measurement: Snellen chart.
© Copyright 2025. All Rights Reserved by MedPath